Xi Venture Capital and Guodiao Fund signed a joint investment agreement for a biopharmaceutical project

　　At the 2022 the Taihu Lake Bay Life and Health Future Conference held on August 4, the company and the National Adjustment Fund signed a contract on the spot for joint investment in three projects, namely, Zhongsheng Tianxinhe (Wuxi) Biotechnology Co., Ltd., Sina Biotechnology (Beijing) Co., Ltd., and Chuangsheng Group Pharmaceutical Co., Ltd. This investment will further enhance the independent and controllable capabilities of upstream raw materials and equipment in China's biopharmaceutical industry. It will also accelerate the gathering of high-end innovation resources at home and abroad, focus on improving innovation capabilities, cultivating leading enterprises, optimizing the development environment, and strengthening original innovation and key core technology research and development.

　　Guodiao Fund is a national level equity investment fund approved by the State Council and established in 2016. It has a total scale of 350 billion yuan and is implemented in three phases, with the second phase landing in Wuxi and a registered capital of 73.75 billion yuan. The fund focuses on investing in important industries, key areas, and major special tasks that are related to national security and the lifeline of the national economy, especially in the fields of biomedicine, integrated circuits and intelligence, advanced manufacturing, artificial intelligence, digital economy, and other industries with industrial advantages in the Yangtze River Delta region.